PDZK1IP1, PDZK1 interacting protein 1, 10158

N. diseases: 46; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.300 Biomarker group CTD_human Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. 17013881 2007
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.300 Biomarker disease CTD_human Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. 17013881 2007
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 Biomarker group BEFREE In a xenograft tumor model in which TGF-β was previously shown to elicit tumor-promoting effects, PDZK1IP1 gain of function decreased tumor size and increased survival rates. 30718277 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 AlteredExpression group BEFREE Fascin-1 and MAP17 are stem cell markers whose excessive expression in tumors is associated with aggressive tumor phenotypes. 31273628 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 AlteredExpression group BEFREE We show that MAP17 expression is induced during lung tumourigenesis, particularly in lung adenocarcinomas, and provide in vitro and in vivo evidence that MAP17 levels predict sensitivity to therapies currently under clinical use in adenocarcinoma tumours, including cisplatin, carboplatin and EGFR inhibitors. 30119639 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 AlteredExpression group BEFREE Conversely, MAP17 downregulation in a tumor cell line constitutively expressing this gene led to Notch pathway inactivation and a marked reduction of stemness. 28153862 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 AlteredExpression group BEFREE Therefore, the combination of high MAP17 and SGLT1 levels is a marker for good prognosis in patients with cervical tumors after cisplatin plus radiotherapy treatment. 23418532 2013
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 AlteredExpression group BEFREE In addition, we show that aberrant promoter hypomethylation-associated overexpression of MAP17 might promote tumor growth in thyroid cancer. 23666970 2013
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 AlteredExpression group BEFREE We have found that MAP17 is expressed in 60% human mammary tumors while it is not expressed in normal or benign neoplasias. 22266858 2012
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 AlteredExpression group BEFREE In addition, DD96 is overexpressed markedly in various human carcinomas originating from the colon, breast, and lung, as well as in a number of cell lines derived from tumors of these organs compared with normal epithelial cell populations. 9815914 1995
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.070 AlteredExpression group BEFREE MAP17 (PDZK1IP1) is a small, 17 kDa non-glycosylated membrane protein located in the plasma membrane and Golgi apparatus and is overexpressed in a wide variety of human carcinomas. 30250642 2018
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.070 AlteredExpression group BEFREE MAP17 is a small nonglycosylated membrane protein that is overexpressed in a high percentage of carcinomas. 25837675 2015
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.070 AlteredExpression group BEFREE MAP17 is a small, 17-kDa, non-glycosylated membrane protein that is overexpressed in a percentage of carcinomas. 22266858 2012
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.070 AlteredExpression group BEFREE We identified MAP17, a small 17 kDa non-glycosylated membrane protein previously identified by differential display being over-expressed in carcinomas. 17548903 2007
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.070 AlteredExpression group BEFREE Taken together, our data show an independent activation of MAP17 promoter that can be driven by oncogenes and that might explain the common overexpression of MAP17 in human carcinomas. 17426052 2007
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.070 AlteredExpression group BEFREE Using in situ hybridization, we demonstrated that MAP17 and PDZK1 mRNAs are markedly up-regulated in human carcinomas. 10496535 1999
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.070 AlteredExpression group BEFREE In addition, DD96 is overexpressed markedly in various human carcinomas originating from the colon, breast, and lung, as well as in a number of cell lines derived from tumors of these organs compared with normal epithelial cell populations. 9815914 1995
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.030 AlteredExpression group BEFREE MAP17 is aberrantly overexpressed in a number of malignancies. 29616128 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.030 Biomarker phenotype BEFREE Furthermore, MAP17 is correlated with tumour progression. 30119639 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.030 Biomarker group BEFREE EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties. 29616128 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.030 Biomarker group BEFREE The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB. 28153862 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.030 Biomarker group BEFREE The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB. 28153862 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.030 Biomarker phenotype BEFREE p38α limits the contribution of MAP17 to cancer progression in breast tumors. 22266858 2012
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.030 Biomarker phenotype BEFREE Immunohistochemical analysis of MAP17 during cancer progression shows, at least in prostate and ovarian carcinomas, that overexpression of the protein strongly correlates with tumoral progression (P < 0.0001). 17426052 2007
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.030 Biomarker group BEFREE Therefore, the protein cluster formed by the association of cMOAT, PDZK1, and MAP17 could play an important role in the cellular mechanisms associated with multidrug resistance, and PDZK1 may represent a new target in cancer cells resistant to chemotherapeutic agents. 10496535 1999